Suzhou, March 16, 2023. Mr. Oskar Gold, Senior Vice President, Asia Pacific and Global Emerging Markets at Vetter, and Mr. Daniel Zhang, Head of Marketing China at Vetter, visited Tarlead Biologic's Suzhou facility.

Jeff Li, CEO of Tarlead Biologic, welcomed the delegation. Both parties exchanged views on topics of mutual interest, including strategies for domestic companies entering international markets and multinational corporations expanding their presence in China. The discussions deepened mutual understanding of each company’s five-year strategic plans and laid the groundwork for potential collaboration.

Mr. Jeff Li, CEO of Tarlead Biologic, stated:

"Comparing the antibody drug market size in China, the US, and Europe, China's mid-to-long-term prospects are highly promising. Meanwhile, demand in mature overseas markets remains robust. For domestic companies—whether biotechs or service providers—seeking global expansion, the advantages lie in 'agility and cost-effectiveness,' while challenges involve 'compliance and processes.' As a global leader in fill-finish services, Vetter offers valuable expertise for Tarlead Biologic to learn from. Moreover, in implementing Vetter’s China strategy and Tarlead Biologic’s overseas expansion strategy, our teams can explore synergies to better serve shared clients."

Mr. Oskar Gold, Senior Vice President, Asia Pacific and Global Emerging Markets at Vetter, stated:

"Leveraging extensive experience, Vetter supports clients in product lifecycle management and offers diverse injection systems. This broad portfolio is accessible to Chinese pharmaceutical and biotech companies. However, compliance with international regulatory standards is critical for market entry. Here, Vetter’s proven track record in global regulatory compliance and deep expertise play a decisive role. For China’s biopharmaceutical industry, our understanding of global requirements significantly aids in preparing documentation for clinical trials and marketing authorization."

During the visit, Mr. Gold and Mr. Zhang toured Tarlead Biologic’s process development laboratories, pilot plant, and GMP production facilities, expressing strong appreciation for the company’s platforms and management systems.

In closing, both parties affirmed their commitment to enhancing future cooperation.